155 related articles for article (PubMed ID: 32526905)
1. Influence of Several Compounds and Drugs on the Renal Uptake of Radiolabeled Affibody Molecules.
Garousi J; Vorobyeva A; Altai M
Molecules; 2020 Jun; 25(11):. PubMed ID: 32526905
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus.
Lindberg H; Hofström C; Altai M; Honorvar H; Wållberg H; Orlova A; Ståhl S; Gräslund T; Tolmachev V
Tumour Biol; 2012 Jun; 33(3):641-51. PubMed ID: 22249974
[TBL] [Abstract][Full Text] [Related]
3. Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein.
Vorobyeva A; Oroujeni M; Lindbo S; Hober S; Xu T; Liu Y; Rinne SS; Garousi J
Molecules; 2020 Sep; 25(19):. PubMed ID: 32998229
[TBL] [Abstract][Full Text] [Related]
4. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties.
Wållberg H; Orlova A; Altai M; Hosseinimehr SJ; Widström C; Malmberg J; Ståhl S; Tolmachev V
J Nucl Med; 2011 Mar; 52(3):461-9. PubMed ID: 21321280
[TBL] [Abstract][Full Text] [Related]
5. Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake.
Ekblad T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsén L; Wennborg A; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2245-55. PubMed ID: 18594815
[TBL] [Abstract][Full Text] [Related]
6. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
7. In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.
Altai M; Varasteh Z; Andersson K; Eek A; Boerman O; Orlova A
Cancer Biother Radiopharm; 2013 Apr; 28(3):187-95. PubMed ID: 23461385
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Evaluation of
Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
[TBL] [Abstract][Full Text] [Related]
9. 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.
Engfeldt T; Tran T; Orlova A; Widström C; Feldwisch J; Abrahmsen L; Wennborg A; Karlström AE; Tolmachev V
Eur J Nucl Med Mol Imaging; 2007 Nov; 34(11):1843-53. PubMed ID: 17565496
[TBL] [Abstract][Full Text] [Related]
10. On the prevention of kidney uptake of radiolabeled DARPins.
Altai M; Garousi J; Rinne SS; Schulga A; Deyev S; Vorobyeva A
EJNMMI Res; 2020 Feb; 10(1):7. PubMed ID: 32020413
[TBL] [Abstract][Full Text] [Related]
11. HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.
Tolmachev V; Hofström C; Malmberg J; Ahlgren S; Hosseinimehr SJ; Sandström M; Abrahmsén L; Orlova A; Gräslund T
Bioconjug Chem; 2010 Nov; 21(11):2013-22. PubMed ID: 20964447
[TBL] [Abstract][Full Text] [Related]
12. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules.
Ekblad T; Orlova A; Feldwisch J; Wennborg A; Karlström AE; Tolmachev V
Bioorg Med Chem Lett; 2009 Jul; 19(14):3912-4. PubMed ID: 19364646
[TBL] [Abstract][Full Text] [Related]
13. Effects of lysine-containing mercaptoacetyl-based chelators on the biodistribution of 99mTc-labeled anti-HER2 Affibody molecules.
Tran TA; Ekblad T; Orlova A; Sandström M; Feldwisch J; Wennborg A; Abrahmsén L; Tolmachev V; Eriksson Karlström A
Bioconjug Chem; 2008 Dec; 19(12):2568-76. PubMed ID: 19035668
[TBL] [Abstract][Full Text] [Related]
14. Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules.
Altai M; Wållberg H; Orlova A; Rosestedt M; Hosseinimehr SJ; Tolmachev V; Ståhl S
Amino Acids; 2012 May; 42(5):1975-85. PubMed ID: 21573874
[TBL] [Abstract][Full Text] [Related]
15. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
16. Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.
Altai M; Honarvar H; Wållberg H; Strand J; Varasteh Z; Rosestedt M; Orlova A; Dunås F; Sandström M; Löfblom J; Tolmachev V; Ståhl S
Eur J Med Chem; 2014 Nov; 87():519-28. PubMed ID: 25282673
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of 99mTc-Z IGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression.
Mitran B; Altai M; Hofström C; Honarvar H; Sandström M; Orlova A; Tolmachev V; Gräslund T
Amino Acids; 2015 Feb; 47(2):303-15. PubMed ID: 25425114
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules.
Tran T; Engfeldt T; Orlova A; Widström C; Bruskin A; Tolmachev V; Karlström AE
Bioconjug Chem; 2007; 18(2):549-58. PubMed ID: 17330952
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-targeting properties of (99m)technetium-labeled cyclic alpha-melanocyte-stimulating hormone peptide analogues.
Chen J; Cheng Z; Hoffman TJ; Jurisson SS; Quinn TP
Cancer Res; 2000 Oct; 60(20):5649-58. PubMed ID: 11059756
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting by an aptamer.
Hicke BJ; Stephens AW; Gould T; Chang YF; Lynott CK; Heil J; Borkowski S; Hilger CS; Cook G; Warren S; Schmidt PG
J Nucl Med; 2006 Apr; 47(4):668-78. PubMed ID: 16595502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
